Gastro-esophageal Reflux Disease (GERD) Completed Phase 3 Trials for Lidocaine (DB00281)

Also known as: Esophageal Reflux / Gastroesophageal Reflux Disease / Gastrooesophageal reflux disease / Gastro-Oesophageal Reflux Disease / Gastro-esophageal Reflux Disease / Gastro-esophageal Reflux Diseases / GERD Gastroesophageal Reflux Disease / GERD (Gastroesophageal Reflux Disease) / GERD / GERD - Gastro-Esophageal Reflux Disease / Gastroesophageal Reflux Disease (GERD) / Oesophageal reflux / Esophagitis / Gastrooesophageal reflux / Gastroesophageal reflux / Esophageal reflux NOS

IndicationStatusPhase
DBCOND0077290 (Gastro-esophageal Reflux Disease (GERD))Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00521703Evaluation of Topical Lidocaine Spray as Adjuvant to Upper Gastrointestinal Endoscopy in ChildrenTreatment